The Global Drug Discovery Services Market was valued at USD 21.17 billion in 2023 and is projected to grow from USD 23.94 billion in 2024 to USD 64.04 billion by 2031, exhibiting a CAGR of 15.09% during the forecast period. The market growth is driven by the rising demand for innovative therapeutics, increasing RD investments, technological advancements, and the growing prevalence of chronic diseases.
Read Complete Report Details: https://www.kingsresearch.com/drug-discovery-services-market-908
Key Market Drivers
1. Rising Prevalence of Chronic Diseases
Increasing cases of cancer, cardiovascular diseases, and neurological disorders.
Demand for novel drugs and personalized medicine is driving RD.
2. Growth in Biopharmaceutical Research Outsourcing
Pharma companies are outsourcing drug discovery services to CROs for cost efficiency.
Expansion of small mid-sized biotech firms looking for external expertise.
3. Advancements in AI Computational Drug Discovery
AI, machine learning, and big data analytics accelerating drug screening candidate selection.
Increased adoption of in silico modeling virtual screening techniques.
4. Rising Government Private Sector Investments
Government grants funding for drug discovery research.
Private equity investments in biotechnology pharmaceutical startups.
5. Expanding Role of Contract Research Organizations (CROs)
Growth of outsourced RD models for drug discovery.
Increased partnerships between biotech firms, academic institutions, and CROs.
Market Segmentation
By Therapeutic Area
Neurology – Driven by rising demand for Alzheimer’s Parkinson’s drugs.
Oncology – Largest segment due to high cancer drug RD investments.
Digestive System Diseases – Growing focus on gastrointestinal metabolic disorders.
Cardiovascular Respiratory Diseases – Increasing cases of heart diseases COPD.
Others – Includes autoimmune diseases, rare diseases, and infectious diseases.
By Process
Target Identification Validation
Hit-to-Lead Identification
Lead Optimization
Candidate Validation Preclinical Studies
By End-User
Pharmaceutical Biotech Companies (Largest share)
Academic Research Institutes
Contract Research Organizations (CROs)
By Type
Medicinal Chemistry
Biology Services
Pharmacokinetics Drug Metabolism Services
By Drug Type
Small Molecule Drugs (Dominant due to ease of manufacturing formulation).
Biologics Large Molecule Drugs (Growing due to advances in monoclonal antibodies gene therapies).
Regional Insights
1. North America (Largest Market)
Strong presence of pharmaceutical giants (Pfizer, Merck, Eli Lilly).
High RD investments in drug discovery technologies.
Growth of AI-driven drug discovery startups.
2. Europe
Government funding for life sciences research.
Major CROs like Charles River and Evotec expanding operations.
Strong presence of academic research institutions biotech hubs.
3. Asia-Pacific (Fastest Growing Region)
Rapid expansion of biopharma companies in China, India South Korea.
Increasing clinical trials contract research services.
Government initiatives supporting drug development infrastructure.
4. Latin America Middle East
Growing investments in pharmaceutical RD in Brazil UAE.
Expansion of local drug development clinical trials.
Competitive Landscape
Key players in the Drug Discovery Services Market include:
Charles River Laboratories
Eurofins Scientific
WuXi AppTec
Evotec SE
Thermo Fisher Scientific
Merck KGaA
Genscript Biotech Corporation
Aptuit (Evotec Company)
These companies focus on strategic collaborations, AI-driven drug discovery, and expansion of research capabilities to maintain a competitive edge.
Future Trends Challenges
Opportunities:
AI machine learning to improve drug discovery efficiency.
Growing focus on personalized medicine biologics.
Expansion of gene therapy regenerative medicine research.
Challenges:
High cost complexity of drug discovery.
Regulatory challenges clinical trial delays.
Intellectual property data security issues in AI-based drug discovery.
Conclusion
The global drug discovery services market is witnessing robust growth, fueled by rising investments in RD, the expansion of CRO partnerships, and AI-driven advancements. North America and Asia-Pacific remain key markets, while innovations in biologics, AI-based screening, and personalized medicine will shape the future of drug discovery.
